Compare Monolithic Power Systems Inc (MPWR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs Summit Therapeutics Inc — how do they compare? Monolithic Power Systems Inc trades at $1,379.55 (market cap $65.28B), while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: Monolithic Power Systems Inc is far larger — about 6.2× Summit Therapeutics Inc's market cap, and Monolithic Power Systems Inc pays a 0.6% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MPWR | SMMT | |
|---|---|---|
Market Cap | $65.28B | $10.48B |
Sector | Utilities | Health |
52-Week High | $1.69K | $29.32 |
52-Week Low | $711.24 | $13.05 |
Enterprise Value | $63.94B | $9.90B |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monolithic Power Systems (MPWR) trades at $1,328.80, up 1.28% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong profitability with a 22.98% net income margin and is set to announce Q2 2026 results on July 30, 2026. Analyst sentiment remains overwhelmingly positive with a consensus price target of $1,780, representing significant upside potential from current levels.
MPWR's outlook is supported by robust fundamentals and AI infrastructure demand, but high valuation multiples and ongoing legal investigations pose risks. The stock offers growth exposure to power management semiconductors, though investors should weigh premium pricing against execution consistency and market volatility.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
